Literature DB >> 15454399

Heart-type fatty acid-binding protein reciprocally regulates glucose and fatty acid utilization during exercise.

Jane Shearer1, Patrick T Fueger, Jeffrey N Rottman, Deanna P Bracy, Bert Binas, David H Wasserman.   

Abstract

The role of heart-type cytosolic fatty acid-binding protein (H-FABP) in mediating whole body and muscle-specific long-chain fatty acid (LCFA) and glucose utilization was examined using exercise as a phenotyping tool. Catheters were chronically implanted in a carotid artery and jugular vein of wild-type (WT, n = 8), heterozygous (H-FABP(+/-), n = 8), and null (H-FABP(-/-), n = 7) chow-fed C57BL/6J mice, and mice were allowed to recover for 7 days. After a 5-h fast, conscious, unrestrained mice were studied during 30 min of treadmill exercise (0.6 mph). A bolus of [(125)I]-15-(p-iodophenyl)-3-R,S-methylpentadecanoic acid and 2-deoxy-[(3)H]glucose was administered to obtain rates of whole body metabolic clearance (MCR) and indexes of muscle LCFA (R(f)) and glucose (R(g)) utilization. Fasting, nonesterified fatty acids (mM) were elevated in H-FABP(-/-) mice (2.2 +/- 0.9 vs. 1.3 +/- 0.1 and 1.3 +/- 0.2 for WT and H-FABP(+/-)). During exercise, blood glucose (mM) increased in WT (11.7 +/- 0.8) and H-FABP(+/-) (12.6 +/- 0.9) mice, whereas H-FABP(-/-) mice developed overt hypoglycemia (4.8 +/- 0.8). Examination of tissue-specific and whole body glucose and LCFA utilization demonstrated a dependency on H-FABP with exercise in all tissues examined. Reductions in H-FABP led to decreasing exercise-stimulated R(f) and increasing R(g) with the most pronounced effects in heart and soleus muscle. Similar results were seen for MCR with decreasing LCFA and increasing glucose clearance with declining levels of H-FABP. These results show that, in vivo, H-FABP has reciprocal effects on glucose and LCFA utilization and whole body fuel homeostasis when metabolic demands are elevated by exercise.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15454399     DOI: 10.1152/ajpendo.00287.2004

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  8 in total

Review 1.  Heart and liver fatty acid binding proteins and the metabolic syndrome.

Authors:  Bert Binas
Journal:  Curr Hypertens Rep       Date:  2005-12       Impact factor: 5.369

2.  Enhanced cardiac protein glycosylation (O-GlcNAc) of selected mitochondrial proteins in rats artificially selected for low running capacity.

Authors:  Virginia L Johnsen; Darrell D Belke; Curtis C Hughey; Dustin S Hittel; Russell T Hepple; Lauren G Koch; Steven L Britton; Jane Shearer
Journal:  Physiol Genomics       Date:  2012-11-06       Impact factor: 3.107

Review 3.  FABPs as determinants of myocellular and hepatic fuel metabolism.

Authors:  B Binas; E Erol
Journal:  Mol Cell Biochem       Date:  2007-05       Impact factor: 3.842

4.  A diurnal serum lipid integrates hepatic lipogenesis and peripheral fatty acid use.

Authors:  Sihao Liu; Jonathan D Brown; Kristopher J Stanya; Edwin Homan; Mathias Leidl; Karen Inouye; Prerna Bhargava; Matthew R Gangl; Lingling Dai; Ben Hatano; Gökhan S Hotamisligil; Alan Saghatelian; Jorge Plutzky; Chih-Hao Lee
Journal:  Nature       Date:  2013-10-24       Impact factor: 49.962

5.  Heart-type fatty-acid-binding protein (FABP3) is a lysophosphatidic acid-binding protein in human coronary artery endothelial cells.

Authors:  Ryoko Tsukahara; Hisao Haniu; Yoshikazu Matsuda; Tamotsu Tsukahara
Journal:  FEBS Open Bio       Date:  2014-10-31       Impact factor: 2.693

6.  Downregulation of low-density lipoprotein receptor mRNA in lymphatic endothelial cells impairs lymphatic function through changes in intracellular lipids.

Authors:  Laurent Vachon; Ali Smaani; Nolwenn Tessier; Gabriel Jean; Annie Demers; Andreea Milasan; Nadine Ardo; Stéphanie Jarry; Louis Villeneuve; Azadeh Alikashani; Vincent Finherty; Matthieu Ruiz; Mary G Sorci-Thomas; Gaétan Mayer; Catherine Martel
Journal:  Theranostics       Date:  2022-01-01       Impact factor: 11.556

7.  Fatty acid binding protein 3 (fabp3) is associated with insulin, lipids and cardiovascular phenotypes of the metabolic syndrome through epigenetic modifications in a Northern European family population.

Authors:  Yi Zhang; Jack W Kent; Adam Lee; Diana Cerjak; Omar Ali; Robert Diasio; Michael Olivier; John Blangero; Melanie A Carless; Ahmed H Kissebah
Journal:  BMC Med Genomics       Date:  2013-03-19       Impact factor: 3.063

8.  Label-Free LC-MS Profiling of Skeletal Muscle Reveals Heart-Type Fatty Acid Binding Protein as a Candidate Biomarker of Aerobic Capacity.

Authors:  Zulezwan Ab Malik; James N Cobley; James P Morton; Graeme L Close; Ben J Edwards; Lauren G Koch; Steven L Britton; Jatin G Burniston
Journal:  Proteomes       Date:  2013-12-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.